Poultry drug developer Embrex (Nasdaq: EMBX) has received marketing approval from the U.S. Department of Agriculture for Newplex, its vaccine for Newcastle disease (ND).
The Newplex vaccine can be delivered into the egg via the Embrex Inovoject system to prevent ND, a respiratory disease that can be fatal to poultry. The vaccine is a proprietary virus-antibody complex that is made by using a patented concept that consists of selecting a suitable vaccine virus and combining it in an appropriate ratio with its specific antibody, which tempers the onset of viral replication.
“USDA approval sets the stage for us to initiate additional regulatory applications in key markets in Asia and Latin America, as well as Mexico,” Embrex President and Chief Executive Randall Marcuson said in a statement. “We believe availability of Newplex vaccine will further support Inovoject system placements in those key markets where Newcastle disease is a costly and serious problem.”